Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02639208
Other study ID # 15-326
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 8, 2016
Est. completion date August 6, 2021

Study information

Verified date August 2021
Source Dana-Farber Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The number of patients 60 and older with breast cancer is increasing as our population ages. Despite the fact that the majority of breast cancers occur in patients 60 and over, these patients are consistently under-represented in clinical trials. Because patients 60 and older are an under-studied group, investigators do not have detailed information on the side effects and experiences for these patients receiving chemotherapy. Understanding the side effects patients receiving chemotherapy experience is an important part of this study. In addition, past research has shown that having poor social support can affect quality of life, mood, and outcomes for people with cancer. However, few studies in the past have focused on improving the quality of life and support systems that patients have while they receive treatment. This research study is evaluating how engaging in an online support community may improve the experience of older patients receiving chemotherapy.


Description:

This clinical trial will evaluate how an on-line health information sharing community of patients called PatientsLikeMe, www.patientslikeme.com, [or "PLM"] may help patients feel better supported during treatment. This study will also evaluate how much PLM can help collect information on side effects from chemotherapy and endocrine treatments, and radiation therapy.


Recruitment information / eligibility

Status Completed
Enrollment 47
Est. completion date August 6, 2021
Est. primary completion date May 2019
Accepts healthy volunteers No
Gender Female
Age group 60 Years and older
Eligibility Inclusion Criteria: - Participants must be women =60 years age with histologically or cytologically confirmed, stage I-III breast cancer with a treatment plan that includes any neoadjuvant or adjuvant chemotherapy(either in the context of standard treatment or a clinical trial and including chemotherapy, treatments targeting the human epidermal growth factor receptor protein 2 [HER2]), hormonal therapy or radiation. - Enrollment must occur according to one of the following: (1) For those receiving chemotherapy/infusional therapy, patients must enroll during the 4 weeks prior to or on the day of treatment initiation, (2) For those enrolling during hormonal therapy and/or radiation, patients must enroll within 6 months of diagnosis of breast cancer, defined as the date of initial biopsy. Patient may be receiving hormonal therapy, radiation therapy, or both at the same time of enrollment, (3) Patients who did not enroll during their chemotherapy are still eligible to enroll during subsequent hormonal therapy or radiation as long as it is within 6 months of diagnosis. - Participants must be approached before start of treatment. Patients must be able to understand, read, and write in English and be able to understand and have willingness to sign a written informed consent document. - Patients are eligible regardless of ECOG performance status, life expectancy or, organ/marrow function. - Patients must have the ability to access the internet at least once per week, and this can occur in the patient's home, relatives' homes, work setting, or Dana-Farber (in addition to coffee shops, libraries, etc if applicable). Having a computer is not required. An iPad will be provided to any patient who needs one for the duration of the study. Exclusion Criteria: - Patients with metastatic breast cancer are not eligible to participate. - Participants who have started their treatment plan are not eligible. - Those unable to understand, read, or write in English are not eligible. - Men are not eligible for this study.

Study Design


Intervention

Other:
PatientsLikeMe (PLM)


Locations

Country Name City State
United States Dana-Farber Cancer Institute Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute CURE Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility/ Rate of Participant Login - PLM We will describe the degree of patient use of the PLM platforms and the associations of short and longer term PLM use with patient characteristics 4-6 months
Secondary Rate of Usability of PLM Usability (how useful they found PLM, what parts of the site they used, etc.) will be assessed using a patient experience survey at the end of the study 6 Months
Secondary Rate of Overall Satisfaction with PLM Satisfaction with the PLM experience wil be assessed using a 'patient experience' survey at the end of the study 6 Months
Secondary Rate of Desirability with PLM Desirability (how much they enjoyed using PLM, etc) wil be assessed using a patient experience survey at the end of the study 6 Months
See also
  Status Clinical Trial Phase
Recruiting NCT05528263 - Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial) N/A
Recruiting NCT03270072 - The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients
Terminated NCT03723863 - Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy N/A
Completed NCT00393341 - Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer N/A
Recruiting NCT05558722 - Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer Phase 2
Active, not recruiting NCT04180579 - Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients N/A
Recruiting NCT03879577 - Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer Phase 2
Withdrawn NCT03058939 - Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer Phase 2
Recruiting NCT05877859 - Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
Recruiting NCT05296746 - Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer Phase 2
Withdrawn NCT05774886 - Implantable Microdevice for TNBC - Pilot Study Phase 1
Completed NCT01599039 - Study the Usefulness of Bio-impedance Spectroscopy in the Early Assessment of Breast Cancer Related Lymphoedema N/A
Unknown status NCT01352494 - Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer Phase 2
Completed NCT03578627 - Stress and Immunity Breast Cancer Project N/A
Recruiting NCT06275126 - Optimizing Surgical Decisions in Young Adults With Breast Cancer N/A
Not yet recruiting NCT05724758 - Patient Reported Outcomes After Oncoplastic Breast Conserving Surgery
Active, not recruiting NCT03766009 - Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making N/A
Recruiting NCT05406531 - The Effectiveness of Psychological Interventions in Psycho-neuroendocrine-immune Network in Breast Cancer Survivors N/A
Active, not recruiting NCT03609047 - Adjuvant Palbociclib in Elderly Patients With Breast Cancer Phase 2
Recruiting NCT05898789 - Virtual Rehabilitation for Cancer Survivors N/A